Open Access<p>Ninjin’yoeito Ameliorates Skeletal Muscle Complications in COPD Model Mice by Upregulating Peroxisome Proliferator-Activated Receptor γ Coactivator-1α Expression</p>
Author(s) -
Atsushi Miyamoto,
Kuniya Asai,
Hideaki Kadotani,
Naomi Maruyama,
Hiroaki Kubo,
Atsuko Okamoto,
Kanako Sato,
Kazuhiro Yamada,
Naoki Ijiri,
Tetsuya Watanabe,
Tomoya Kawaguchi
Publication year - 2020
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s280401
Subject(s) - medicine , copd , skeletal muscle , sarcopenia , endocrinology , peroxisome proliferator activated receptor , bronchoalveolar lavage , soleus muscle , receptor , lung
Sarcopenia, the loss of skeletal muscle mass and strength, is a common systemic consequence of chronic obstructive pulmonary disease (COPD) and is correlated with higher mortality. Ninjin'yoeito (NYT) is a Japanese herbal medicine used to treat athrepsia and anorexia and is reported to ameliorate weight loss and muscular dysfunction. Recent studies have shown that its crude components upregulate the peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α)-related pathway, which is involved in skeletal muscle functions. Here, we examined whether NYT improves skeletal muscle complications by upregulating PGC-1α in COPD model mice.